#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0245] As is also disclosed in International Publication WO 02/36603, "Also the expression pattern is very similar between the various species as can be taken from the following table [Sullivan K.
1-1	0-1	[	_	_	
1-2	1-5	0245	_	_	
1-3	5-6	]	_	_	
1-4	7-9	As	_	_	
1-5	10-12	is	_	_	
1-6	13-17	also	_	_	
1-7	18-27	disclosed	_	_	
1-8	28-30	in	_	_	
1-9	31-44	International	_	_	
1-10	45-56	Publication	_	_	
1-11	57-59	WO	_	_	
1-12	60-62	02	_	_	
1-13	62-63	/	_	_	
1-14	63-68	36603	_	_	
1-15	68-69	,	_	_	
1-16	70-71	"	_	_	
1-17	71-75	Also	_	_	
1-18	76-79	the	_	_	
1-19	80-90	expression	_	_	
1-20	91-98	pattern	_	_	
1-21	99-101	is	_	_	
1-22	102-106	very	_	_	
1-23	107-114	similar	_	_	
1-24	115-122	between	_	_	
1-25	123-126	the	_	_	
1-26	127-134	various	_	_	
1-27	135-142	species	_	_	
1-28	143-145	as	_	_	
1-29	146-149	can	_	_	
1-30	150-152	be	_	_	
1-31	153-158	taken	_	_	
1-32	159-163	from	_	_	
1-33	164-167	the	_	_	
1-34	168-177	following	_	_	
1-35	178-183	table	_	_	
1-36	184-185	[	_	_	
1-37	185-193	Sullivan	_	_	
1-38	194-195	K	_	_	
1-39	195-196	.	_	_	

#Text=F., 1988, Arm.
2-1	197-198	F	_	_	
2-2	198-199	.	_	_	
2-3	199-200	,	_	_	
2-4	201-205	1988	_	_	
2-5	205-206	,	_	_	
2-6	207-210	Arm	_	_	
2-7	210-211	.	_	_	

#Text=Rev.
3-1	212-215	Rev	_	_	
3-2	215-216	.	_	_	

#Text=Cell Biol. 4: 687-716] which comprises the respective human members of each class . . .
4-1	217-221	Cell	_	_	
4-2	222-226	Biol	_	_	
4-3	226-227	.	_	_	
4-4	228-229	4	_	_	
4-5	229-230	:	_	_	
4-6	231-234	687	_	_	
4-7	234-235	-	_	_	
4-8	235-238	716	_	_	
4-9	238-239	]	_	_	
4-10	240-245	which	_	_	
4-11	246-255	comprises	_	_	
4-12	256-259	the	_	_	
4-13	260-270	respective	_	_	
4-14	271-276	human	_	_	
4-15	277-284	members	_	_	
4-16	285-287	of	_	_	
4-17	288-292	each	_	_	
4-18	293-298	class	_	_	
4-19	299-300	.	_	_	
4-20	301-302	.	_	_	
4-21	303-304	.	_	_	

#Text=The C terminal end of the beta-tubulins starting from amino acid 430 is regarded as highly variable between the various classes.
5-1	305-308	The	_	_	
5-2	309-310	C	_	_	
5-3	311-319	terminal	_	_	
5-4	320-323	end	_	_	
5-5	324-326	of	_	_	
5-6	327-330	the	_	_	
5-7	331-344	beta-tubulins	_	_	
5-8	345-353	starting	_	_	
5-9	354-358	from	_	_	
5-10	359-364	amino	_	_	
5-11	365-369	acid	_	_	
5-12	370-373	430	_	_	
5-13	374-376	is	_	_	
5-14	377-385	regarded	_	_	
5-15	386-388	as	_	_	
5-16	389-395	highly	_	_	
5-17	396-404	variable	_	_	
5-18	405-412	between	_	_	
5-19	413-416	the	_	_	
5-20	417-424	various	_	_	
5-21	425-432	classes	_	_	
5-22	432-433	.	_	_	

#Text=Additionally, the members of the same class seem to be very conserved between the various species."
#Text=[0246] As is also disclosed in International Publication WO 02/36603, "As tubulin molecules are involved in many processes and form part of many structures in the eucaryotic cell, they are possible targets for pharmaceutically active compounds.
6-1	434-446	Additionally	_	_	
6-2	446-447	,	_	_	
6-3	448-451	the	_	_	
6-4	452-459	members	_	_	
6-5	460-462	of	_	_	
6-6	463-466	the	_	_	
6-7	467-471	same	_	_	
6-8	472-477	class	_	_	
6-9	478-482	seem	_	_	
6-10	483-485	to	_	_	
6-11	486-488	be	_	_	
6-12	489-493	very	_	_	
6-13	494-503	conserved	_	_	
6-14	504-511	between	_	_	
6-15	512-515	the	_	_	
6-16	516-523	various	_	_	
6-17	524-531	species	_	_	
6-18	531-532	.	_	_	
6-19	532-533	"	_	_	
6-20	534-535	[	_	_	
6-21	535-539	0246	_	_	
6-22	539-540	]	_	_	
6-23	541-543	As	_	_	
6-24	544-546	is	_	_	
6-25	547-551	also	_	_	
6-26	552-561	disclosed	_	_	
6-27	562-564	in	_	_	
6-28	565-578	International	_	_	
6-29	579-590	Publication	_	_	
6-30	591-593	WO	_	_	
6-31	594-596	02	_	_	
6-32	596-597	/	_	_	
6-33	597-602	36603	_	_	
6-34	602-603	,	_	_	
6-35	604-605	"	_	_	
6-36	605-607	As	_	_	
6-37	608-615	tubulin	_	_	
6-38	616-625	molecules	_	_	
6-39	626-629	are	_	_	
6-40	630-638	involved	_	_	
6-41	639-641	in	_	_	
6-42	642-646	many	_	_	
6-43	647-656	processes	_	_	
6-44	657-660	and	_	_	
6-45	661-665	form	_	_	
6-46	666-670	part	_	_	
6-47	671-673	of	_	_	
6-48	674-678	many	_	_	
6-49	679-689	structures	_	_	
6-50	690-692	in	_	_	
6-51	693-696	the	_	_	
6-52	697-707	eucaryotic	_	_	
6-53	708-712	cell	_	_	
6-54	712-713	,	_	_	
6-55	714-718	they	_	_	
6-56	719-722	are	_	_	
6-57	723-731	possible	_	_	
6-58	732-739	targets	_	_	
6-59	740-743	for	_	_	
6-60	744-760	pharmaceutically	_	_	
6-61	761-767	active	_	_	
6-62	768-777	compounds	_	_	
6-63	777-778	.	_	_	

#Text=As tubulin is more particularly the main structural component of the microtubules it may act as point of attack for anticancer drugs such as vinblastin, colchicin, estramustin and taxol which interfere with microtubule function.
7-1	779-781	As	_	_	
7-2	782-789	tubulin	_	_	
7-3	790-792	is	_	_	
7-4	793-797	more	_	_	
7-5	798-810	particularly	_	_	
7-6	811-814	the	_	_	
7-7	815-819	main	_	_	
7-8	820-830	structural	_	_	
7-9	831-840	component	_	_	
7-10	841-843	of	_	_	
7-11	844-847	the	_	_	
7-12	848-860	microtubules	_	_	
7-13	861-863	it	_	_	
7-14	864-867	may	_	_	
7-15	868-871	act	_	_	
7-16	872-874	as	_	_	
7-17	875-880	point	_	_	
7-18	881-883	of	_	_	
7-19	884-890	attack	_	_	
7-20	891-894	for	_	_	
7-21	895-905	anticancer	_	_	
7-22	906-911	drugs	_	_	
7-23	912-916	such	_	_	
7-24	917-919	as	_	_	
7-25	920-930	vinblastin	_	_	
7-26	930-931	,	_	_	
7-27	932-941	colchicin	_	_	
7-28	941-942	,	_	_	
7-29	943-954	estramustin	_	_	
7-30	955-958	and	_	_	
7-31	959-964	taxol	_	_	
7-32	965-970	which	_	_	
7-33	971-980	interfere	_	_	
7-34	981-985	with	_	_	
7-35	986-997	microtubule	_	_	
7-36	998-1006	function	_	_	
7-37	1006-1007	.	_	_	

#Text=The mode of action is such that cytostatic agents such as the ones mentioned above, bind to the carboxyterminal end the beta-tubulin which upon such binding undergoes a conformational change.
8-1	1008-1011	The	_	_	
8-2	1012-1016	mode	_	_	
8-3	1017-1019	of	_	_	
8-4	1020-1026	action	_	_	
8-5	1027-1029	is	_	_	
8-6	1030-1034	such	_	_	
8-7	1035-1039	that	_	_	
8-8	1040-1050	cytostatic	_	_	
8-9	1051-1057	agents	_	_	
8-10	1058-1062	such	_	_	
8-11	1063-1065	as	_	_	
8-12	1066-1069	the	_	_	
8-13	1070-1074	ones	_	_	
8-14	1075-1084	mentioned	_	_	
8-15	1085-1090	above	_	_	
8-16	1090-1091	,	_	_	
8-17	1092-1096	bind	_	_	
8-18	1097-1099	to	_	_	
8-19	1100-1103	the	_	_	
8-20	1104-1119	carboxyterminal	_	_	
8-21	1120-1123	end	_	_	
8-22	1124-1127	the	_	_	
8-23	1128-1140	beta-tubulin	_	_	
8-24	1141-1146	which	_	_	
8-25	1147-1151	upon	_	_	
8-26	1152-1156	such	_	_	
8-27	1157-1164	binding	_	_	
8-28	1165-1174	undergoes	_	_	
8-29	1175-1176	a	_	_	
8-30	1177-1191	conformational	_	_	
8-31	1192-1198	change	_	_	
8-32	1198-1199	.	_	_	

#Text=For example, Kavallaris et al.
9-1	1200-1203	For	_	_	
9-2	1204-1211	example	_	_	
9-3	1211-1212	,	_	_	
9-4	1213-1223	Kavallaris	_	_	
9-5	1224-1226	et	_	_	
9-6	1227-1229	al	_	_	
9-7	1229-1230	.	_	_	

#Text=[Kavallaris et al. 1997, J.
10-1	1231-1232	[	_	_	
10-2	1232-1242	Kavallaris	_	_	
10-3	1243-1245	et	_	_	
10-4	1246-1248	al	_	_	
10-5	1248-1249	.	_	_	
10-6	1250-1254	1997	_	_	
10-7	1254-1255	,	_	_	
10-8	1256-1257	J	_	_	
10-9	1257-1258	.	_	_	

#Text=Clin.
11-1	1259-1263	Clin	_	_	
11-2	1263-1264	.	_	_	

#Text=Invest. 100: 1282-1293] reported a change in the expression of of specific beta-tubulin isotypes (class I, II, III, and IVa) in taxol resistant epithelial ovarian tumor.
12-1	1265-1271	Invest	_	_	
12-2	1271-1272	.	_	_	
12-3	1273-1276	100	_	_	
12-4	1276-1277	:	_	_	
12-5	1278-1282	1282	_	_	
12-6	1282-1283	-	_	_	
12-7	1283-1287	1293	_	_	
12-8	1287-1288	]	_	_	
12-9	1289-1297	reported	_	_	
12-10	1298-1299	a	_	_	
12-11	1300-1306	change	_	_	
12-12	1307-1309	in	_	_	
12-13	1310-1313	the	_	_	
12-14	1314-1324	expression	_	_	
12-15	1325-1327	of	_	_	
12-16	1328-1330	of	_	_	
12-17	1331-1339	specific	_	_	
12-18	1340-1352	beta-tubulin	_	_	
12-19	1353-1361	isotypes	_	_	
12-20	1362-1363	(	_	_	
12-21	1363-1368	class	_	_	
12-22	1369-1370	I	_	_	
12-23	1370-1371	,	_	_	
12-24	1372-1374	II	_	_	
12-25	1374-1375	,	_	_	
12-26	1376-1379	III	_	_	
12-27	1379-1380	,	_	_	
12-28	1381-1384	and	_	_	
12-29	1385-1388	IVa	_	_	
12-30	1388-1389	)	_	_	
12-31	1390-1392	in	_	_	
12-32	1393-1398	taxol	_	_	
12-33	1399-1408	resistant	_	_	
12-34	1409-1419	epithelial	_	_	
12-35	1420-1427	ovarian	_	_	
12-36	1428-1433	tumor	_	_	
12-37	1433-1434	.	_	_	

#Text=It was concluded that these tubulins are involved in the formation of the taxol resistence.
13-1	1435-1437	It	_	_	
13-2	1438-1441	was	_	_	
13-3	1442-1451	concluded	_	_	
13-4	1452-1456	that	_	_	
13-5	1457-1462	these	_	_	
13-6	1463-1471	tubulins	_	_	
13-7	1472-1475	are	_	_	
13-8	1476-1484	involved	_	_	
13-9	1485-1487	in	_	_	
13-10	1488-1491	the	_	_	
13-11	1492-1501	formation	_	_	
13-12	1502-1504	of	_	_	
13-13	1505-1508	the	_	_	
13-14	1509-1514	taxol	_	_	
13-15	1515-1525	resistence	_	_	
13-16	1525-1526	.	_	_	

#Text=Also a high expression of class III beta--tubulins was found in some forms of lung cancer suggesting that this isotype may be used as a diagnostic marker."
#Text=[0247] As is also disclosed in International Publication WO 02/36603, "The problem underlying the present invention was to provide the means to further characterize the various tubulins present in eucaryotic cells.
14-1	1527-1531	Also	_	_	
14-2	1532-1533	a	_	_	
14-3	1534-1538	high	_	_	
14-4	1539-1549	expression	_	_	
14-5	1550-1552	of	_	_	
14-6	1553-1558	class	_	_	
14-7	1559-1562	III	_	_	
14-8	1563-1567	beta	_	_	
14-9	1567-1568	-	_	_	
14-10	1568-1569	-	_	_	
14-11	1569-1577	tubulins	_	_	
14-12	1578-1581	was	_	_	
14-13	1582-1587	found	_	_	
14-14	1588-1590	in	_	_	
14-15	1591-1595	some	_	_	
14-16	1596-1601	forms	_	_	
14-17	1602-1604	of	_	_	
14-18	1605-1609	lung	_	_	
14-19	1610-1616	cancer	_	_	
14-20	1617-1627	suggesting	_	_	
14-21	1628-1632	that	_	_	
14-22	1633-1637	this	_	_	
14-23	1638-1645	isotype	_	_	
14-24	1646-1649	may	_	_	
14-25	1650-1652	be	_	_	
14-26	1653-1657	used	_	_	
14-27	1658-1660	as	_	_	
14-28	1661-1662	a	_	_	
14-29	1663-1673	diagnostic	_	_	
14-30	1674-1680	marker	_	_	
14-31	1680-1681	.	_	_	
14-32	1681-1682	"	_	_	
14-33	1683-1684	[	_	_	
14-34	1684-1688	0247	_	_	
14-35	1688-1689	]	_	_	
14-36	1690-1692	As	_	_	
14-37	1693-1695	is	_	_	
14-38	1696-1700	also	_	_	
14-39	1701-1710	disclosed	_	_	
14-40	1711-1713	in	_	_	
14-41	1714-1727	International	_	_	
14-42	1728-1739	Publication	_	_	
14-43	1740-1742	WO	_	_	
14-44	1743-1745	02	_	_	
14-45	1745-1746	/	_	_	
14-46	1746-1751	36603	_	_	
14-47	1751-1752	,	_	_	
14-48	1753-1754	"	_	_	
14-49	1754-1757	The	_	_	
14-50	1758-1765	problem	_	_	
14-51	1766-1776	underlying	_	_	
14-52	1777-1780	the	_	_	
14-53	1781-1788	present	_	_	
14-54	1789-1798	invention	_	_	
14-55	1799-1802	was	_	_	
14-56	1803-1805	to	_	_	
14-57	1806-1813	provide	_	_	
14-58	1814-1817	the	_	_	
14-59	1818-1823	means	_	_	
14-60	1824-1826	to	_	_	
14-61	1827-1834	further	_	_	
14-62	1835-1847	characterize	_	_	
14-63	1848-1851	the	_	_	
14-64	1852-1859	various	_	_	
14-65	1860-1868	tubulins	_	_	
14-66	1869-1876	present	_	_	
14-67	1877-1879	in	_	_	
14-68	1880-1890	eucaryotic	_	_	
14-69	1891-1896	cells	_	_	
14-70	1896-1897	.	_	_	

#Text=A further problem underlying the present invention was to provide the means to extend possible screening programs for cytostatic agents to other isotypes of human beta-tubulins.
15-1	1898-1899	A	_	_	
15-2	1900-1907	further	_	_	
15-3	1908-1915	problem	_	_	
15-4	1916-1926	underlying	_	_	
15-5	1927-1930	the	_	_	
15-6	1931-1938	present	_	_	
15-7	1939-1948	invention	_	_	
15-8	1949-1952	was	_	_	
15-9	1953-1955	to	_	_	
15-10	1956-1963	provide	*[1]	16-1[2_1]|19-2[3_1]	
15-11	1964-1967	the	*[1]	_	
15-12	1968-1973	means	*[1]	_	
15-13	1974-1976	to	*[1]	_	
15-14	1977-1983	extend	*[1]	_	
15-15	1984-1992	possible	*[1]	_	
15-16	1993-2002	screening	*[1]	_	
15-17	2003-2011	programs	*[1]	_	
15-18	2012-2015	for	*[1]	_	
15-19	2016-2026	cytostatic	*[1]	_	
15-20	2027-2033	agents	*[1]	_	
15-21	2034-2036	to	*[1]	_	
15-22	2037-2042	other	*[1]	_	
15-23	2043-2051	isotypes	*[1]	_	
15-24	2052-2054	of	*[1]	_	
15-25	2055-2060	human	*[1]	_	
15-26	2061-2074	beta-tubulins	*[1]	_	
15-27	2074-2075	.	*[1]	_	

#Text=This problem is solved in a first aspect by a nucleic acid molecule comprising a nucleotide sequence encoding a tubulin molecule, wherein said nucleic acid molecule comprises the sequence according to SEQ.
16-1	2076-2080	This	*[2]	_	
16-2	2081-2088	problem	*[2]	_	
16-3	2089-2091	is	_	_	
16-4	2092-2098	solved	_	_	
16-5	2099-2101	in	_	_	
16-6	2102-2103	a	_	_	
16-7	2104-2109	first	_	_	
16-8	2110-2116	aspect	_	_	
16-9	2117-2119	by	_	_	
16-10	2120-2121	a	_	_	
16-11	2122-2129	nucleic	_	_	
16-12	2130-2134	acid	_	_	
16-13	2135-2143	molecule	_	_	
16-14	2144-2154	comprising	_	_	
16-15	2155-2156	a	_	_	
16-16	2157-2167	nucleotide	_	_	
16-17	2168-2176	sequence	_	_	
16-18	2177-2185	encoding	_	_	
16-19	2186-2187	a	_	_	
16-20	2188-2195	tubulin	_	_	
16-21	2196-2204	molecule	_	_	
16-22	2204-2205	,	_	_	
16-23	2206-2213	wherein	_	_	
16-24	2214-2218	said	_	_	
16-25	2219-2226	nucleic	_	_	
16-26	2227-2231	acid	_	_	
16-27	2232-2240	molecule	_	_	
16-28	2241-2250	comprises	_	_	
16-29	2251-2254	the	_	_	
16-30	2255-2263	sequence	_	_	
16-31	2264-2273	according	_	_	
16-32	2274-2276	to	_	_	
16-33	2277-2280	SEQ	_	_	
16-34	2280-2281	.	_	_	

#Text=ID.
17-1	2282-2284	ID	_	_	
17-2	2284-2285	.	_	_	

#Text=No.
18-1	2286-2288	No	_	_	
18-2	2288-2289	.	_	_	

#Text=I This problem is `solved in a second aspect by a nucleic acid molecule comprising a nucleotide sequence encoding a tubulin molecule, wherein said nucleic acid molecule comprises the sequence according to SEQ.1D.
19-1	2290-2291	I	_	_	
19-2	2292-2296	This	*[3]	_	
19-3	2297-2304	problem	*[3]	_	
19-4	2305-2307	is	_	_	
19-5	2308-2309	`	_	_	
19-6	2309-2315	solved	_	_	
19-7	2316-2318	in	_	_	
19-8	2319-2320	a	_	_	
19-9	2321-2327	second	_	_	
19-10	2328-2334	aspect	_	_	
19-11	2335-2337	by	_	_	
19-12	2338-2339	a	_	_	
19-13	2340-2347	nucleic	_	_	
19-14	2348-2352	acid	_	_	
19-15	2353-2361	molecule	_	_	
19-16	2362-2372	comprising	_	_	
19-17	2373-2374	a	_	_	
19-18	2375-2385	nucleotide	_	_	
19-19	2386-2394	sequence	_	_	
19-20	2395-2403	encoding	_	_	
19-21	2404-2405	a	_	_	
19-22	2406-2413	tubulin	_	_	
19-23	2414-2422	molecule	_	_	
19-24	2422-2423	,	_	_	
19-25	2424-2431	wherein	_	_	
19-26	2432-2436	said	_	_	
19-27	2437-2444	nucleic	_	_	
19-28	2445-2449	acid	_	_	
19-29	2450-2458	molecule	_	_	
19-30	2459-2468	comprises	_	_	
19-31	2469-2472	the	_	_	
19-32	2473-2481	sequence	_	_	
19-33	2482-2491	according	_	_	
19-34	2492-2494	to	_	_	
19-35	2495-2498	SEQ	_	_	
19-36	2498-2501	.1D	_	_	
19-37	2501-2502	.	_	_	

#Text=No. 2 . . . "
#Text=[0248] Published U.S. patent application 2002/0106705, the entire disclosure of which is hereby incorporated by reference into this specification, describes a method for detecting a modified beta-tubulin isotype.
20-1	2503-2505	No	_	_	
20-2	2505-2506	.	_	_	
20-3	2507-2508	2	_	_	
20-4	2509-2510	.	_	_	
20-5	2511-2512	.	_	_	
20-6	2513-2514	.	_	_	
20-7	2515-2516	"	_	_	
20-8	2517-2518	[	_	_	
20-9	2518-2522	0248	_	_	
20-10	2522-2523	]	_	_	
20-11	2524-2533	Published	_	_	
20-12	2534-2537	U.S	_	_	
20-13	2537-2538	.	_	_	
20-14	2539-2545	patent	_	_	
20-15	2546-2557	application	_	_	
20-16	2558-2562	2002	_	_	
20-17	2562-2563	/	_	_	
20-18	2563-2570	0106705	_	_	
20-19	2570-2571	,	_	_	
20-20	2572-2575	the	_	_	
20-21	2576-2582	entire	_	_	
20-22	2583-2593	disclosure	_	_	
20-23	2594-2596	of	_	_	
20-24	2597-2602	which	_	_	
20-25	2603-2605	is	_	_	
20-26	2606-2612	hereby	_	_	
20-27	2613-2625	incorporated	_	_	
20-28	2626-2628	by	_	_	
20-29	2629-2638	reference	_	_	
20-30	2639-2643	into	_	_	
20-31	2644-2648	this	_	_	
20-32	2649-2662	specification	_	_	
20-33	2662-2663	,	_	_	
20-34	2664-2673	describes	_	_	
20-35	2674-2675	a	_	_	
20-36	2676-2682	method	_	_	
20-37	2683-2686	for	_	_	
20-38	2687-2696	detecting	_	_	
20-39	2697-2698	a	_	_	
20-40	2699-2707	modified	_	_	
20-41	2708-2720	beta-tubulin	_	_	
20-42	2721-2728	isotype	_	_	
20-43	2728-2729	.	_	_	

#Text=Claim 1 of this patent, which is typical, describes: "A method of detecting in a sample a .beta.
21-1	2730-2735	Claim	_	_	
21-2	2736-2737	1	_	_	
21-3	2738-2740	of	_	_	
21-4	2741-2745	this	_	_	
21-5	2746-2752	patent	_	_	
21-6	2752-2753	,	_	_	
21-7	2754-2759	which	_	_	
21-8	2760-2762	is	_	_	
21-9	2763-2770	typical	_	_	
21-10	2770-2771	,	_	_	
21-11	2772-2781	describes	_	_	
21-12	2781-2782	:	_	_	
21-13	2783-2784	"	_	_	
21-14	2784-2785	A	_	_	
21-15	2786-2792	method	_	_	
21-16	2793-2795	of	_	_	
21-17	2796-2805	detecting	_	_	
21-18	2806-2808	in	_	_	
21-19	2809-2810	a	_	_	
21-20	2811-2817	sample	_	_	
21-21	2818-2819	a	_	_	
21-22	2820-2821	.	_	_	
21-23	2821-2825	beta	_	_	
21-24	2825-2826	.	_	_	

#Text=-tubulin isotype modified at cysteine residue 239, the method comprising the steps of: (a) providing a sample treated with a .beta.
22-1	2826-2827	-	_	_	
22-2	2827-2834	tubulin	_	_	
22-3	2835-2842	isotype	_	_	
22-4	2843-2851	modified	_	_	
22-5	2852-2854	at	_	_	
22-6	2855-2863	cysteine	_	_	
22-7	2864-2871	residue	_	_	
22-8	2872-2875	239	_	_	
22-9	2875-2876	,	_	_	
22-10	2877-2880	the	_	_	
22-11	2881-2887	method	_	_	
22-12	2888-2898	comprising	_	_	
22-13	2899-2902	the	_	_	
22-14	2903-2908	steps	_	_	
22-15	2909-2911	of	_	_	
22-16	2911-2912	:	_	_	
22-17	2913-2914	(	_	_	
22-18	2914-2915	a	_	_	
22-19	2915-2916	)	_	_	
22-20	2917-2926	providing	_	_	
22-21	2927-2928	a	_	_	
22-22	2929-2935	sample	_	_	
22-23	2936-2943	treated	_	_	
22-24	2944-2948	with	_	_	
22-25	2949-2950	a	_	_	
22-26	2951-2952	.	_	_	
22-27	2952-2956	beta	_	_	
22-28	2956-2957	.	_	_	

#Text=-tubulin modifying agent; (b) contacting the sample with an antibody that specifically binds to a .beta.
23-1	2957-2958	-	_	_	
23-2	2958-2965	tubulin	_	_	
23-3	2966-2975	modifying	_	_	
23-4	2976-2981	agent	_	_	
23-5	2981-2982	;	_	_	
23-6	2983-2984	(	_	_	
23-7	2984-2985	b	_	_	
23-8	2985-2986	)	_	_	
23-9	2987-2997	contacting	_	_	
23-10	2998-3001	the	_	_	
23-11	3002-3008	sample	_	_	
23-12	3009-3013	with	_	_	
23-13	3014-3016	an	_	_	
23-14	3017-3025	antibody	_	_	
23-15	3026-3030	that	_	_	
23-16	3031-3043	specifically	_	_	
23-17	3044-3049	binds	_	_	
23-18	3050-3052	to	_	_	
23-19	3053-3054	a	_	_	
23-20	3055-3056	.	_	_	
23-21	3056-3060	beta	_	_	
23-22	3060-3061	.	_	_	

#Text=-tubulin isotype modified at cysteine residue 239; and (c) determining whether the sample contains a modified .beta.
24-1	3061-3062	-	_	_	
24-2	3062-3069	tubulin	_	_	
24-3	3070-3077	isotype	_	_	
24-4	3078-3086	modified	_	_	
24-5	3087-3089	at	_	_	
24-6	3090-3098	cysteine	_	_	
24-7	3099-3106	residue	_	_	
24-8	3107-3110	239	_	_	
24-9	3110-3111	;	_	_	
24-10	3112-3115	and	_	_	
24-11	3116-3117	(	_	_	
24-12	3117-3118	c	_	_	
24-13	3118-3119	)	_	_	
24-14	3120-3131	determining	_	_	
24-15	3132-3139	whether	_	_	
24-16	3140-3143	the	_	_	
24-17	3144-3150	sample	_	_	
24-18	3151-3159	contains	_	_	
24-19	3160-3161	a	_	_	
24-20	3162-3170	modified	_	_	
24-21	3171-3172	.	_	_	
24-22	3172-3176	beta	_	_	
24-23	3176-3177	.	_	_	

#Text=-tubulin isotype by detecting the antibody."
25-1	3177-3178	-	_	_	
25-2	3178-3185	tubulin	_	_	
25-3	3186-3193	isotype	_	_	
25-4	3194-3196	by	_	_	
25-5	3197-3206	detecting	_	_	
25-6	3207-3210	the	_	_	
25-7	3211-3219	antibody	_	_	
25-8	3219-3220	.	_	_	
25-9	3220-3221	"	_	_	

#Text=This patent discloses that: "Microtubules are composed of .alpha./.beta.
26-1	3222-3226	This	_	_	
26-2	3227-3233	patent	_	_	
26-3	3234-3243	discloses	_	_	
26-4	3244-3248	that	_	_	
26-5	3248-3249	:	_	_	
26-6	3250-3251	"	_	_	
26-7	3251-3263	Microtubules	_	_	
26-8	3264-3267	are	_	_	
26-9	3268-3276	composed	_	_	
26-10	3277-3279	of	_	_	
26-11	3280-3281	.	_	_	
26-12	3281-3286	alpha	_	_	
26-13	3286-3287	.	_	_	
26-14	3287-3288	/	_	_	
26-15	3288-3289	.	_	_	
26-16	3289-3293	beta	_	_	
26-17	3293-3294	.	_	_	

#Text=-tubulin heterodimers and constitute a crucial component of the cell cytoskeleton.
27-1	3294-3295	-	_	_	
27-2	3295-3302	tubulin	_	_	
27-3	3303-3315	heterodimers	_	_	
27-4	3316-3319	and	_	_	
27-5	3320-3330	constitute	_	_	
27-6	3331-3332	a	_	_	
27-7	3333-3340	crucial	_	_	
27-8	3341-3350	component	_	_	
27-9	3351-3353	of	_	_	
27-10	3354-3357	the	_	_	
27-11	3358-3362	cell	_	_	
27-12	3363-3375	cytoskeleton	_	_	
27-13	3375-3376	.	_	_	

#Text=Furthermore, microtubules play a pivotal role during cell division, in particular when the replicated chromosomes are separated during mitosis.
28-1	3377-3388	Furthermore	_	_	
28-2	3388-3389	,	_	_	
28-3	3390-3402	microtubules	_	_	
28-4	3403-3407	play	_	_	
28-5	3408-3409	a	_	_	
28-6	3410-3417	pivotal	_	_	
28-7	3418-3422	role	_	_	
28-8	3423-3429	during	_	_	
28-9	3430-3434	cell	_	_	
28-10	3435-3443	division	_	_	
28-11	3443-3444	,	_	_	
28-12	3445-3447	in	_	_	
28-13	3448-3458	particular	_	_	
28-14	3459-3463	when	_	_	
28-15	3464-3467	the	_	_	
28-16	3468-3478	replicated	_	_	
28-17	3479-3490	chromosomes	_	_	
28-18	3491-3494	are	_	_	
28-19	3495-3504	separated	_	_	
28-20	3505-3511	during	_	_	
28-21	3512-3519	mitosis	_	_	
28-22	3519-3520	.	_	_	

#Text=Interference with the ability to form microtubules from .alpha./.beta.
29-1	3521-3533	Interference	_	_	
29-2	3534-3538	with	_	_	
29-3	3539-3542	the	_	_	
29-4	3543-3550	ability	_	_	
29-5	3551-3553	to	_	_	
29-6	3554-3558	form	_	_	
29-7	3559-3571	microtubules	_	_	
29-8	3572-3576	from	_	_	
29-9	3577-3578	.	_	_	
29-10	3578-3583	alpha	_	_	
29-11	3583-3584	.	_	_	
29-12	3584-3585	/	_	_	
29-13	3585-3586	.	_	_	
29-14	3586-3590	beta	_	_	
29-15	3590-3591	.	_	_	

#Text=-tubulin heterodimeric subunits generally leads to cell cycle arrest.
30-1	3591-3592	-	_	_	
30-2	3592-3599	tubulin	_	_	
30-3	3600-3613	heterodimeric	_	_	
30-4	3614-3622	subunits	_	_	
30-5	3623-3632	generally	_	_	
30-6	3633-3638	leads	_	_	
30-7	3639-3641	to	_	_	
30-8	3642-3646	cell	_	_	
30-9	3647-3652	cycle	_	_	
30-10	3653-3659	arrest	_	_	
30-11	3659-3660	.	_	_	

#Text=This event can, in certain cases, induce programmed cell death.
31-1	3661-3665	This	_	_	
31-2	3666-3671	event	_	_	
31-3	3672-3675	can	_	_	
31-4	3675-3676	,	_	_	
31-5	3677-3679	in	_	_	
31-6	3680-3687	certain	_	_	
31-7	3688-3693	cases	_	_	
31-8	3693-3694	,	_	_	
31-9	3695-3701	induce	_	_	
31-10	3702-3712	programmed	_	_	
31-11	3713-3717	cell	_	_	
31-12	3718-3723	death	_	_	
31-13	3723-3724	.	_	_	

#Text=Thus, natural products and organic compounds that interfere with microtubule formation have been used successfully as chemotherapeutic agents in the treatment of various human cancers."
#Text=[0249] Published United States paent application 2002/0106705 also discloses that: "Pentafluorophenylsulfonamidobenzenes and related sulfhydryl and disulfide modifying agents (see, e.g., compound 1; 2-fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene . . . prevent microtubule formation by selectively covalently modifying .beta.
32-1	3725-3729	Thus	_	_	
32-2	3729-3730	,	_	_	
32-3	3731-3738	natural	_	_	
32-4	3739-3747	products	_	_	
32-5	3748-3751	and	_	_	
32-6	3752-3759	organic	_	_	
32-7	3760-3769	compounds	_	_	
32-8	3770-3774	that	_	_	
32-9	3775-3784	interfere	_	_	
32-10	3785-3789	with	_	_	
32-11	3790-3801	microtubule	_	_	
32-12	3802-3811	formation	_	_	
32-13	3812-3816	have	_	_	
32-14	3817-3821	been	_	_	
32-15	3822-3826	used	_	_	
32-16	3827-3839	successfully	_	_	
32-17	3840-3842	as	_	_	
32-18	3843-3859	chemotherapeutic	_	_	
32-19	3860-3866	agents	_	_	
32-20	3867-3869	in	_	_	
32-21	3870-3873	the	_	_	
32-22	3874-3883	treatment	_	_	
32-23	3884-3886	of	_	_	
32-24	3887-3894	various	_	_	
32-25	3895-3900	human	_	_	
32-26	3901-3908	cancers	_	_	
32-27	3908-3909	.	_	_	
32-28	3909-3910	"	_	_	
32-29	3911-3912	[	_	_	
32-30	3912-3916	0249	_	_	
32-31	3916-3917	]	_	_	
32-32	3918-3927	Published	_	_	
32-33	3928-3934	United	_	_	
32-34	3935-3941	States	_	_	
32-35	3942-3947	paent	_	_	
32-36	3948-3959	application	_	_	
32-37	3960-3964	2002	_	_	
32-38	3964-3965	/	_	_	
32-39	3965-3972	0106705	_	_	
32-40	3973-3977	also	_	_	
32-41	3978-3987	discloses	_	_	
32-42	3988-3992	that	_	_	
32-43	3992-3993	:	_	_	
32-44	3994-3995	"	_	_	
32-45	3995-4031	Pentafluorophenylsulfonamidobenzenes	_	_	
32-46	4032-4035	and	_	_	
32-47	4036-4043	related	_	_	
32-48	4044-4054	sulfhydryl	_	_	
32-49	4055-4058	and	_	_	
32-50	4059-4068	disulfide	_	_	
32-51	4069-4078	modifying	_	_	
32-52	4079-4085	agents	_	_	
32-53	4086-4087	(	_	_	
32-54	4087-4090	see	_	_	
32-55	4090-4091	,	_	_	
32-56	4092-4095	e.g	_	_	
32-57	4095-4096	.	_	_	
32-58	4096-4097	,	_	_	
32-59	4098-4106	compound	_	_	
32-60	4107-4108	1	_	_	
32-61	4108-4109	;	_	_	
32-62	4110-4111	2	_	_	
32-63	4111-4112	-	_	_	
32-64	4112-4118	fluoro	_	_	
32-65	4118-4119	-	_	_	
32-66	4119-4120	1	_	_	
32-67	4120-4121	-	_	_	
32-68	4121-4128	methoxy	_	_	
32-69	4128-4129	-	_	_	
32-70	4129-4130	4	_	_	
32-71	4130-4131	-	_	_	
32-72	4131-4166	pentafluorophenylsulfonamidobenzene	_	_	
32-73	4167-4168	.	_	_	
32-74	4169-4170	.	_	_	
32-75	4171-4172	.	_	_	
32-76	4173-4180	prevent	_	_	
32-77	4181-4192	microtubule	_	_	
32-78	4193-4202	formation	_	_	
32-79	4203-4205	by	_	_	
32-80	4206-4217	selectively	_	_	
32-81	4218-4228	covalently	_	_	
32-82	4229-4238	modifying	_	_	
32-83	4239-4240	.	_	_	
32-84	4240-4244	beta	_	_	
32-85	4244-4245	.	_	_	

#Text=-tubulin.
33-1	4245-4246	-	_	_	
33-2	4246-4253	tubulin	_	_	
33-3	4253-4254	.	_	_	

#Text=For example, compound 1 does not covalently modify all of the five known .beta.
34-1	4255-4258	For	_	_	
34-2	4259-4266	example	_	_	
34-3	4266-4267	,	_	_	
34-4	4268-4276	compound	_	_	
34-5	4277-4278	1	_	_	
34-6	4279-4283	does	_	_	
34-7	4284-4287	not	_	_	
34-8	4288-4298	covalently	_	_	
34-9	4299-4305	modify	_	_	
34-10	4306-4309	all	_	_	
34-11	4310-4312	of	_	_	
34-12	4313-4316	the	_	_	
34-13	4317-4321	five	_	_	
34-14	4322-4327	known	_	_	
34-15	4328-4329	.	_	_	
34-16	4329-4333	beta	_	_	
34-17	4333-4334	.	_	_	

#Text=-tubulin isotypes.
35-1	4334-4335	-	_	_	
35-2	4335-4342	tubulin	_	_	
35-3	4343-4351	isotypes	_	_	
35-4	4351-4352	.	_	_	

#Text=Instead, binding is restricted to those .beta.
36-1	4353-4360	Instead	_	_	
36-2	4360-4361	,	_	_	
36-3	4362-4369	binding	_	_	
36-4	4370-4372	is	_	_	
36-5	4373-4383	restricted	_	_	
36-6	4384-4386	to	_	_	
36-7	4387-4392	those	_	_	
36-8	4393-4394	.	_	_	
36-9	4394-4398	beta	_	_	
36-10	4398-4399	.	_	_	

#Text=-tubulin isotypes that have a cysteine residue at amino acid position 239 in .beta.
37-1	4399-4400	-	_	_	
37-2	4400-4407	tubulin	_	_	
37-3	4408-4416	isotypes	_	_	
37-4	4417-4421	that	_	_	
37-5	4422-4426	have	_	_	
37-6	4427-4428	a	_	_	
37-7	4429-4437	cysteine	_	_	
37-8	4438-4445	residue	_	_	
37-9	4446-4448	at	_	_	
37-10	4449-4454	amino	_	_	
37-11	4455-4459	acid	_	_	
37-12	4460-4468	position	_	_	
37-13	4469-4472	239	_	_	
37-14	4473-4475	in	_	_	
37-15	4476-4477	.	_	_	
37-16	4477-4481	beta	_	_	
37-17	4481-4482	.	_	_	

#Text=-tubulin.
38-1	4482-4483	-	_	_	
38-2	4483-4490	tubulin	_	_	
38-3	4490-4491	.	_	_	

#Text=Such isotypes include .beta.1, .beta.2 and .beta.4-tubulin.
39-1	4492-4496	Such	_	_	
39-2	4497-4505	isotypes	_	_	
39-3	4506-4513	include	_	_	
39-4	4514-4515	.	_	_	
39-5	4515-4519	beta	_	_	
39-6	4519-4521	.1	_	_	
39-7	4521-4522	,	_	_	
39-8	4523-4524	.	_	_	
39-9	4524-4528	beta	_	_	
39-10	4528-4530	.2	_	_	
39-11	4531-4534	and	_	_	
39-12	4535-4536	.	_	_	
39-13	4536-4540	beta	_	_	
39-14	4540-4542	.4	_	_	
39-15	4542-4543	-	_	_	
39-16	4543-4550	tubulin	_	_	
39-17	4550-4551	.	_	_	

#Text=The other two isotypes (.beta.3 and .beta.5) have a serine residue at this particular position (Shan et al., Proc.
40-1	4552-4555	The	_	_	
40-2	4556-4561	other	_	_	
40-3	4562-4565	two	_	_	
40-4	4566-4574	isotypes	_	_	
40-5	4575-4576	(	_	_	
40-6	4576-4577	.	_	_	
40-7	4577-4581	beta	_	_	
40-8	4581-4583	.3	_	_	
40-9	4584-4587	and	_	_	
40-10	4588-4589	.	_	_	
40-11	4589-4593	beta	_	_	
40-12	4593-4595	.5	_	_	
40-13	4595-4596	)	_	_	
40-14	4597-4601	have	_	_	
40-15	4602-4603	a	_	_	
40-16	4604-4610	serine	_	_	
40-17	4611-4618	residue	_	_	
40-18	4619-4621	at	_	_	
40-19	4622-4626	this	_	_	
40-20	4627-4637	particular	_	_	
40-21	4638-4646	position	_	_	
40-22	4647-4648	(	_	_	
40-23	4648-4652	Shan	_	_	
40-24	4653-4655	et	_	_	
40-25	4656-4658	al	_	_	
40-26	4658-4659	.	_	_	
40-27	4659-4660	,	_	_	
40-28	4661-4665	Proc	_	_	
40-29	4665-4666	.	_	_	

#Text=Nat'l Acad.
41-1	4667-4672	Nat'l	_	_	
41-2	4673-4677	Acad	_	_	
41-3	4677-4678	.	_	_	

#Text=Sci USA 96:5686-5691 (1999)).
42-1	4679-4682	Sci	_	_	
42-2	4683-4686	USA	_	_	
42-3	4687-4689	96	_	_	
42-4	4689-4690	:	_	_	
42-5	4690-4694	5686	_	_	
42-6	4694-4695	-	_	_	
42-7	4695-4699	5691	_	_	
42-8	4700-4701	(	_	_	
42-9	4701-4705	1999	_	_	
42-10	4705-4706	)	_	_	
42-11	4706-4707	)	_	_	
42-12	4707-4708	.	_	_	

#Text=It is notable that no other cellular proteins are modified by compound 1."
43-1	4709-4711	It	_	_	
43-2	4712-4714	is	_	_	
43-3	4715-4722	notable	_	_	
43-4	4723-4727	that	_	_	
43-5	4728-4730	no	_	_	
43-6	4731-4736	other	_	_	
43-7	4737-4745	cellular	_	_	
43-8	4746-4754	proteins	_	_	
43-9	4755-4758	are	_	_	
43-10	4759-4767	modified	_	_	
43-11	4768-4770	by	_	_	
43-12	4771-4779	compound	_	_	
43-13	4780-4781	1	_	_	
43-14	4781-4782	.	_	_	
43-15	4782-4783	"	_	_	
